HMGB1 was increased in the serum of tumor-bearing mice 7 d after treatment with Flt3L and TK (*p < 0.05; η2 = 0.49; Figure 7C), suggesting that HMGB1 released from dying tumor cells might be responsible for activating TLR2 on DC in vivo and subsequent T cell-dependent tumor regression. Here, HMGB1 is linked to neoplasm.